Get the Stockscreener App
126.16
1.79%
-2.30
After Hours:
126.16
Jazz Pharmaceuticals Plc stock is traded at $126.16, with a volume of 559.94K.
It is down -1.79% in the last 24 hours and up +11.32% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$128.46
Open:
$127.93
24h Volume:
559.94K
Relative Volume:
0.77
Market Cap:
$7.65B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
17.77
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-2.58%
1M Performance:
+11.32%
6M Performance:
-5.96%
1Y Performance:
+18.52%
1-Day Range:
$126.07
$128.54
1-Week Range:
$125.33
$130.28
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
126.16 | 7.70B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Hancock Whitney Corp Takes Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Great Lakes Advisors LLC Has $6.85 Million Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Amundi Decreases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AQR Capital Management LLC Sells 43,375 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
NFJ Investment Group LLC Purchases New Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Cubist Systematic Strategies LLC Boosts Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem - Seeking Alpha
150,000 Narcolepsy Patients Get New Option: Amneal's FDA-Approved Generic Breaks Single-Maker Market - Stock Titan
Dynamic Technology Lab Private Ltd Buys New Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Petrus Trust Company LTA Buys Shares of 6,272 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
$7B GW Pharma Exit Veteran Justin Gover Joins Design Therapeutics Board to Advance Genetic Disease Pipeline - Stock Titan
How Investors Are Reacting To Jazz Pharmaceuticals (JAZZ) Gaining Accelerated FDA Approval for Modeyso in Rare Brain Tumors - simplywall.st
Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More - Yahoo Finance
Adage Capital Partners GP L.L.C. Makes New Investment in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Estuary Capital Management LP Grows Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Jazz Pharmaceuticals’ Modeyso added to NCCN guidelines for rare brain tumor - Investing.com
JAZZ: FDA Supports Jazz Pharmaceuticals' Modeyso for High-Grade Glioma - GuruFocus
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma - PR Newswire
AQR Arbitrage LLC Has $11 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Can Jazz Pharmaceuticals plc disrupt its industryPortfolio Profit Report & Expert-Curated Trade Recommendations - 뉴스영
Published on: 2025-09-08 13:29:20 - beatles.ru
Can Jazz Pharmaceuticals plc grow without dilutionJuly 2025 Review & High Accuracy Trade Alerts - classian.co.kr
Published on: 2025-09-06 04:29:55 - Newser
Canada Pension Plan Investment Board Has $21.93 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Trexquant Investment LP Buys 14,781 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
The Manufacturers Life Insurance Company Has $63.99 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Cozadd Bruce C, director at Jazz Pharmaceuticals, sells $771k in stock - Investing.com Australia
Driehaus Capital Management LLC Purchases Shares of 90,550 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Will Jazz Pharmaceuticals plc be affected by tariffs2025 Technical Overview & Daily Momentum Trading Reports - خودرو بانک
Building trade automation scripts for Jazz Pharmaceuticals plcJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355 - MSN
Risk vs reward if holding onto Jazz Pharmaceuticals plcInflation Watch & Free Expert Verified Stock Movement Alerts - Newser
Comparing Jazz Pharmaceuticals plc in custom built stock radarsGold Moves & High Accuracy Trade Alerts - Newser
Jump Financial LLC Invests $550,000 in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Will Jazz Pharmaceuticals plc rebound enough to break evenWeekly Trend Recap & Fast Entry Momentum Alerts - Newser
Predicting Jazz Pharmaceuticals plc trend using moving averagesTrade Entry Report & Smart Money Movement Tracker - Newser
Will Jazz Pharmaceuticals plc bounce back from current supportEarnings Growth Summary & Daily Technical Forecast Reports - Newser
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC - GuruFocus
Is Jazz Pharmaceuticals plc a potential multi baggerJuly 2025 Big Picture & High Accuracy Investment Signals - خودرو بانک
Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update - MSN
Jazz Pharmaceuticals Insider Selling: Signal of Concern or a Strategic Move? - AInvest
Evaluating Jazz Pharmaceuticals plc with trendline analysisJuly 2025 Recap & Expert Approved Momentum Trade Ideas - Newser
Will Jazz Pharmaceuticals plc price bounce be sustainable2025 Investor Takeaways & Short-Term Trading Alerts - Newser
Pattern recognition hints at Jazz Pharmaceuticals plc upside2025 Sector Review & Risk Adjusted Buy and Sell Alerts - Newser
What technical models suggest about Jazz Pharmaceuticals plc’s comebackAnalyst Upgrade & Real-Time Stock Entry Alerts - Newser
How to use Fibonacci retracement on Jazz Pharmaceuticals plcMarket Activity Report & Advanced Swing Trade Entry Plans - Newser
Transcript : Jazz Pharmaceuticals plc Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 09 - MarketScreener
Synovus Financial Corp Sells 15,507 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):